We treat our clients’ projects as if they are our own. From a genuine interest, we maintain a close relationship with our clients, in which we value open and honest communication, in order to provide high quality, tailored solutions. Together we achieve more. That is why we assemble the best team together with our clients to integrate all the required expertise. In order to do so, we combine in-house expertise with external KOLs. We look beyond borders and connect all relevant parties, ranging from patients to investors, from academia to pharma.
From A to Z
We provide all core expertise needed to take a drug development program from A to B or from A to Z, if required. Whether you are looking for a complete development program design or temporary replacement, we find solutions for any challenge.
Combining decades of experience in drug development has led to the fact that today 3D has a well-known reputation for combining our experience in the industry with scientific expertise and our mission is clear; to partner with you from early on to the very end.
Industry Expertise
As a well-known player in the drug development landscape, we have partnered with an abundance of companies with products ranging from small molecules to modern-day ATMPs.
Additionally, all our staff are industry seasoned professionals making us a partner that’s known for:
- Operational efficiency
- Familiarity with the industry’s processes
- Internal flexibility to deliver tailored expertise
Scientific Expertise
The people at 3D-PharmXChange are all experts in their own fields. On top of this, they are all professionals who work well in teams, maximizing their unique competences and creating value proposition that sets us apart from the competition.
Without exception, they have professional and scientific expertise that allow them to:
- Set up a feasible development plans
- Listen critically and identify GAPs
- Create added value in your drug development
Three Reasons
As a company, we strive to exceed our clients’ expectations and aim to offer them an optimal balance of expertise, experience, and continuous improvement.
Working with 3D-PharmXchange means working with a motivated team that is Dedicated to accelerating Drug Development.
1. Dedicated
Dedicated to our clients
2. Drug
From Small Molecule To ATMP
3. Development
All Throughout Development
Our Managing Partners
The management team consists of three seasoned professionals from the Life Sciences industry with complementary strengths and skillsets that have realized a reputation for excellence in drug development today.
Ronald van der Geest
A PhD-level clinical pharmacologist and drug delivery expert. Besides being a serial entrepreneur in the life sciences sector, he currently fulfills development leader roles within several biotech companies.
François van Och
At 3D, François combines his experience in leadership and as an expert toxicologist. He takes responsibility for the company’s operations and leads client projects in toxicology, DMPK, biopharmaceutics and early clinical research.
Inez de Greef – van der Sandt
In addition to being a partner at 3D, Inez is the CEO of Treeway, a biotechnology company developing therapies for ALS. Over the years, she has been involved in many drug development projects with a focus on clinical development.

Partners
The management team consists of three seasoned professionals from the Life Sciences industry with complementary strengths and skillsets that have realized a reputation for excellence in drug development today.
Ronald van der Geest
A PhD-level clinical pharmacologist and drug delivery expert who is well-known for his role in leading the development of Glybera™ for uniQure, the 1st approved gene therapy product.

François van Och
At 3D, François combines his experience in leadership and as an expert toxicologist. He takes responsibility for the company’s operations and leads client projects in toxicology, DMPK, biopharmaceutics and early clinical research.

Inez de Greef – van der Sandt
In addition to being a partner at 3D, Inez is the CEO of Treeway, a biotechnology company developing therapies for ALS. Over the years, she has been involved in many drug development projects with a focus on clinical development.
